Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT) is a global company in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences. This news page aggregates announcements, press releases, and corporate updates related to Waters, giving readers a focused view of developments that affect the company and its markets.
Investors and industry professionals can use this feed to follow Waters’ product launches, financial results, and strategic initiatives. Recent news has highlighted new technologies such as the Xevo Charge Detection Mass Spectrometer (CDMS), which Waters describes as enabling direct mass detection for large biomolecules relevant to next-generation therapeutics, and a Charged Aerosol Detector designed for use with the company’s Empower chromatography data system. These announcements illustrate how Waters is addressing analytical challenges in pharmaceuticals, biotherapeutics, food analysis, and environmental testing.
The news stream also features quarterly earnings releases, where Waters reports sales performance, instrument and recurring revenue trends, and commentary from management. In addition, Waters issues updates on investor conference presentations and on the planned combination with BD’s Biosciences & Diagnostic Solutions business via a Reverse Morris Trust transaction, as described in its press releases and Form 8-K filings.
By reviewing Waters-related news in one place, readers can track themes such as instrument replacement cycles, adoption of new chromatography and mass spectrometry products, and the company’s expansion into adjacencies like bioseparations, bioanalytical characterization, and multiplex diagnostics. Bookmark this page to monitor ongoing disclosures and media releases that shape the narrative around WAT stock and Waters’ role in regulated, high-volume testing and scientific markets.
Waters (NYSE:WAT) has announced its upcoming Investor Day scheduled for March 5th, 2025, in New York City, beginning at 8:30 AM ET. The event will showcase presentations from senior management, highlighting business achievements, strategic priorities, and future value creation plans, followed by a Q&A session.
The company is offering both in-person attendance and live webcast options, with registration available through the Waters Investor Relations website. A replay of the webcast will be accessible after the event concludes.
Waters is a global leader in analytical instruments and software, known for innovations in chromatography, mass spectrometry, and thermal analysis. The company employs approximately 7,500 people worldwide, operates in 35 countries with 15 manufacturing facilities, and distributes products in over 100 countries.
Waters (NYSE: WAT) has been named to the Dow Jones Sustainability North America Index (DJSI North America) for the fourth consecutive year, surpassing industry averages across all sustainability categories. The company achieved its greenhouse gas reduction target two years early in 2023 and made progress in STEM education advancement.
Waters has committed to setting science-based emission reduction targets aligned with the SBTi's criteria for a 1.5°C future. Notable achievements include building Massachusetts' first LEED-certified chemical manufacturing facility in 2022 and opening a 45,000 square foot BREEAM Very Good standard facility in the UK's West Midlands with an 'A' rated Energy Performance Certificate.
The DJSI recognition is based on the S&P Global Corporate Sustainability Assessment, which evaluates over 13,000 companies worldwide on industry-specific and financially material sustainability criteria.
Waters (NYSE:WAT) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Udit Batra Ph.D. will engage in a fireside chat on January 13th, 2025, at 2:15 PM Pacific Time. The event will be accessible via live webcast on Waters' Investor Relations website, with replay available for 90 days.
Waters is a global leader in analytical instruments and software, known for innovations in chromatography, mass spectrometry, and thermal analysis. The company serves life, materials, food, and environmental sciences sectors, employing approximately 7,500 people worldwide. Waters maintains direct operations in 35 countries, including 15 manufacturing facilities, with products available in over 100 countries.
Waters (NYSE: WAT) has reported significant progress in its sustainability commitments, exceeding its greenhouse gas emissions reduction target two years ahead of schedule with a 36% reduction from 2016 baseline. The company has achieved notable environmental milestones, including a 50% decrease in landfill waste and a 29% reduction in water use intensity.
In social initiatives, Waters expanded its STEM education efforts through the Waters Student Academy, reaching over 380 students and increasing candidate diversity in recruitment by 6%. The company introduced the University Pathways Program to support career development and diversify talent pipeline.
Waters received recognition as the 2024 Public Company Board of the Year by NACD New England Chapter and was included in Barron's 2024 100 Most Sustainable Companies. The company has committed to science-based emission reduction targets aligned with SBTi's 1.5°C criteria.
Waters (NYSE:WAT) announced its participation in the 7th Annual Evercore HealthCONx Conference. CEO Udit Batra will join a fireside chat on December 4th, 2024, at 10:00 AM Eastern Time. The event will be livestreamed on Waters' Investor Relations website, with a replay available for 90 days.
Waters is a global leader in analytical instruments and software, specializing in chromatography, mass spectrometry, and thermal analysis innovations. The company employs approximately 7,500 people worldwide, operates in 35 countries with 15 manufacturing facilities, and distributes products in over 100 countries.
Waters (NYSE:WAT) has opened a new 45,000 square foot manufacturing facility at Longbridge Business Park, UK. The facility triples the company's manufacturing footprint and enhances machining capacity for components used in mass spectrometry systems. Built to BREEAM Very Good standard with an 'A' Energy Performance Certificate rating, the facility features zero natural gas consumption for heating and maintains temperature-controlled production for sub-micron accuracy manufacturing. The expansion represents a significant investment in the region and supports Waters' Mass Spectrometry Centers in Wilmslow, UK and Wexford, Ireland.
Waters (NYSE: WAT) has announced waters_connect Data Intelligence software, a new cloud-based application designed to enhance laboratory data management and audit readiness. The software integrates with Waters Empower Chromatography Data System (CDS) to provide comprehensive business intelligence on chromatographic data. Key features include real-time audit response capabilities, risk visibility for regulatory compliance, and system suitability monitoring that could help prevent failures estimated to cost up to $600,000 annually. The software will be available for ordering in December 2024.
Waters (NYSE: WAT) reported strong Q3 2024 results with sales of $740 million, up 4% from Q3 2023. The company exceeded guidance across key metrics, with GAAP EPS of $2.71 and non-GAAP EPS of $2.93. All regions and end markets showed growth, with pharmaceutical market sales up 2%, industrial market sales increasing 9%, and academic/government market sales rising 2%. Instrument systems sales grew 1%, while recurring revenues increased 6%. The company raised its full-year 2024 guidance, expecting Q4 constant currency sales growth of 5% to 7%.
Waters (NYSE: WAT) has introduced new bioseparations tools to accelerate and improve the development of RNA-based pharmaceuticals. The comprehensive set includes:
1. Novel digestion enzymes (RapiZyme MC1 and RapiZyme Cusativin) for complete RNA sequence coverage.
2. LC-MS-grade reagents (IonHance HFIP) to increase sensitivity and improve detection accuracy.
3. waters_connect MAP Sequence software for semi-automated workflows, reducing data processing time.
These tools simplify large molecule RNA analysis, supporting the development of mRNA vaccines, personalized cancer therapies, and drugs for genetic disorders. The new products aim to enhance sequence confirmation, modification analysis, and overall characterization of complex RNA molecules, potentially accelerating therapeutic development and lowering barriers for LC-MS non-experts.
Waters (NYSE:WAT) has introduced the TA Instruments™ Discovery Core Rheometer, a streamlined analyzer designed for routine manufacturing quality control and assurance laboratories. This compact system offers:
- Easy-to-use touchscreen interface with self-guided training, methods, and applications
- Superior performance at an affordable price, with up to 2x better torque sensitivity compared to similar rheometers
- Compact design requiring half the bench space of comparable modular rheometers
- Ability to handle multiple material types such as battery slurries, printing inks, food, and personal care products
The Discovery Core Rheometer is equipped with RheoGuide™ Software, providing immediate walk-up use and faster, real-time data analysis. It is orderable today, with worldwide availability in Q1 2025.